Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD

1.22  +0.01 (+0.83%)

After market: 1.22 0 (0%)

Fundamental Rating

2

Overall AKYA gets a fundamental rating of 2 out of 10. We evaluated AKYA against 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of AKYA have multiple concerns. AKYA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKYA had negative earnings in the past year.
AKYA had a negative operating cash flow in the past year.
AKYA had negative earnings in each of the past 5 years.
AKYA had a negative operating cash flow in each of the past 5 years.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -44.29%, AKYA is doing worse than 83.93% of the companies in the same industry.
AKYA has a Return On Equity of -728.97%. This is amonst the worse of the industry: AKYA underperforms 91.07% of its industry peers.
Industry RankSector Rank
ROA -44.29%
ROE -728.97%
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 58.62%, AKYA is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
In the last couple of years the Gross Margin of AKYA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AKYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AKYA has been increased compared to 1 year ago.
The number of shares outstanding for AKYA has been increased compared to 5 years ago.
The debt/assets ratio for AKYA is higher compared to a year ago.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -2.85. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
AKYA has a Altman-Z score of -2.85. This is amonst the worse of the industry: AKYA underperforms 85.71% of its industry peers.
A Debt/Equity ratio of 10.12 is on the high side and indicates that AKYA has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 10.12, AKYA is doing worse than 92.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.12
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACC12.24%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

AKYA has a Current Ratio of 2.61. This indicates that AKYA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.61, AKYA perfoms like the industry average, outperforming 44.64% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that AKYA should not have too much problems paying its short term obligations.
AKYA's Quick ratio of 1.78 is in line compared to the rest of the industry. AKYA outperforms 41.07% of its industry peers.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 1.78
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

AKYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.98%, which is quite impressive.
Looking at the last year, AKYA shows a very negative growth in Revenue. The Revenue has decreased by -15.49% in the last year.
The Revenue has been growing by 14.10% on average over the past years. This is quite good.
EPS 1Y (TTM)20.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)-15.49%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-19.42%

3.2 Future

The Earnings Per Share is expected to grow by 12.72% on average over the next years. This is quite good.
AKYA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.45% yearly.
EPS Next Y42.23%
EPS Next 2Y24.81%
EPS Next 3Y15.92%
EPS Next 5Y12.72%
Revenue Next Year10.84%
Revenue Next 2Y12.41%
Revenue Next 3Y10.64%
Revenue Next 5Y10.45%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

AKYA's earnings are expected to grow with 15.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.81%
EPS Next 3Y15.92%

More info and screens

0

5. Dividend

5.1 Amount

AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (5/2/2025, 8:00:00 PM)

After market: 1.22 0 (0%)

1.22

+0.01 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)05-20 2025-05-20/amc
Inst Owners34.52%
Inst Owner Change0.36%
Ins Owners4.61%
Ins Owner Change11.98%
Market Cap60.80M
Analysts52.31
Price Target3.05 (150%)
Short Float %N/A
Short Ratio8.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.81%
Min EPS beat(2)-2.56%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-16.36%
Min EPS beat(4)-62.97%
Max EPS beat(4)1.15%
EPS beat(8)4
Avg EPS beat(8)-2.1%
EPS beat(12)4
Avg EPS beat(12)-5.89%
EPS beat(16)5
Avg EPS beat(16)-130.7%
Revenue beat(2)0
Avg Revenue beat(2)-14.69%
Min Revenue beat(2)-27.44%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-14.71%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)4
Avg Revenue beat(8)-6.51%
Revenue beat(12)8
Avg Revenue beat(12)-2.64%
Revenue beat(16)10
Avg Revenue beat(16)-1.86%
PT rev (1m)-14.08%
PT rev (3m)-14.57%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)0.18%
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-3.02%
Revenue NQ rev (1m)0.43%
Revenue NQ rev (3m)-1%
Revenue NY rev (1m)-0.95%
Revenue NY rev (3m)-0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.74
P/FCF N/A
P/OCF N/A
P/B 8.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS1.64
BVpS0.15
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.29%
ROE -728.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.62%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 10.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.09%
Cap/Sales 3.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 1.78
Altman-Z -2.85
F-Score3
WACC12.24%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y42.23%
EPS Next 2Y24.81%
EPS Next 3Y15.92%
EPS Next 5Y12.72%
Revenue 1Y (TTM)-15.49%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-19.42%
Revenue Next Year10.84%
Revenue Next 2Y12.41%
Revenue Next 3Y10.64%
Revenue Next 5Y10.45%
EBIT growth 1Y29.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.25%
EBIT Next 3Y20.4%
EBIT Next 5Y16.7%
FCF growth 1Y14.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.35%
OCF growth 3YN/A
OCF growth 5YN/A